Stay updated on Pembrolizumab with BCG in HR NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.
Latest updates to the Pembrolizumab with BCG in HR NMIBC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe website has added new dates including 2024-12-11 and 2034-11-20, and updated to Revision v2.13.3, while removing several dates and reverting to an earlier version, v2.13.2.SummaryDifference0.3%
- Check16 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference1%
- Check24 days agoChange DetectedNew entries were added on November 22 and November 26, 2024, while entries from November 14 and November 18, 2024, were removed.SummaryDifference0.1%
- Check31 days agoChange DetectedThe Institute of Science Tokyo Hospital has been added as a new site, while numerous study coordinator contact details have been removed, indicating a significant update in site management and contact information.SummaryDifference14%
- Check52 days agoChange DetectedThe website has been updated from version v2.11.2 to v2.12.1.SummaryDifference0.1%
- Check70 days agoChange DetectedNew study numbers and definitions related to carcinoma in situ (CIS) response metrics have been added, while similar entries from previous dates have been removed.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab with BCG in HR NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.